CAM
AEGR

Capstone Asset Management’s Aegerion Pharmaceuticals AEGR Stock Holding History

Capstone Asset Management’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-2,941
Closed -$252K – 2010
2013
Q3 		$252K Buy
+2,941
New +$249K 0.01% 1744

Other funds holding AEGR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capstone Asset Management's AEGR Position: Q4 2013 in Review

Capstone Asset Management sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2013, closing a stake of 2,941 shares — an estimated $252K sold.

Capstone Asset Management first reported a position in AEGR in Q3 2013 and held it in 1 quarter. The position peaked at $252K in Q3 2013. 150 funds tracked by Wall St. Rank hold AEGR as of Q4 2013.

  • Capstone Asset Management reported no remaining Aegerion Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Capstone Asset Management sold 2,941 Aegerion Pharmaceuticals shares in Q4 2013, an estimated $252K.
  • Capstone Asset Management first reported a position in Aegerion Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Capstone Asset Management's Aegerion Pharmaceuticals position peaked at $252K in Q3 2013.
  • 150 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2013.

Based on Capstone Asset Management's 13F filing for Q4 2013, filed 4 Feb 2014.